Abstract
Purpose: Development of a controlled delivery of metoprolol tartrate using the synergistic activity of locust bean gum (LBG) and Xanthan gum (X). Method: Metoprolol tartrate granules were prepared using different ratios of drug: gum (X, LBG and mixture of XLBG). To increase the flowability and compressibility of the granules, and to prevent its adhesion to punch and die, magnesium stearate and talc were added to the granules in 1:2 ratio respectively before punching. The tablets were analysed for their hardness, friability, % assay and in vitro release study was carried out. Results: The release of drug from a gelatinous swollen mass, which controls the diffusion of drug molecules through the polymeric material into aqueous medium. The XLBG matrices show precise controlled release than the X and LBG matrices because of burst effect and fast release in case of X and LBG alone respectively. FTIR and DSC thermogram studies confirmed that there was no chemical interaction between drug and polymers in XLBG formulation. First pass effect of metoprolol tartrate can be avoided by this formulation. However, according to the similarity factor (f2) XLBG3 was most similar to Meto-ER as the reference standard. Conclusion: The XLBG matrices leads to more precise result than X and LBG matrices due the utilization of synergistic interaction between two biopolymers and lower average size of this allowing a uniformity with the tablet hydration in dissolution media.
Keywords: Locust bean gum, xanthan gum, metoprolol tartrate, controlled release
Current Drug Therapy
Title: Xanthan and Locust Bean Gum (from Ceratonia siliqua) Matrix Tablets for Oral Controlled Delivery of Metoprolol Tartrate
Volume: 3 Issue: 1
Author(s): M. P. Venkataraju, D. V. Gowda, K S. Rajesh and H. G. Shivakumar
Affiliation:
Keywords: Locust bean gum, xanthan gum, metoprolol tartrate, controlled release
Abstract: Purpose: Development of a controlled delivery of metoprolol tartrate using the synergistic activity of locust bean gum (LBG) and Xanthan gum (X). Method: Metoprolol tartrate granules were prepared using different ratios of drug: gum (X, LBG and mixture of XLBG). To increase the flowability and compressibility of the granules, and to prevent its adhesion to punch and die, magnesium stearate and talc were added to the granules in 1:2 ratio respectively before punching. The tablets were analysed for their hardness, friability, % assay and in vitro release study was carried out. Results: The release of drug from a gelatinous swollen mass, which controls the diffusion of drug molecules through the polymeric material into aqueous medium. The XLBG matrices show precise controlled release than the X and LBG matrices because of burst effect and fast release in case of X and LBG alone respectively. FTIR and DSC thermogram studies confirmed that there was no chemical interaction between drug and polymers in XLBG formulation. First pass effect of metoprolol tartrate can be avoided by this formulation. However, according to the similarity factor (f2) XLBG3 was most similar to Meto-ER as the reference standard. Conclusion: The XLBG matrices leads to more precise result than X and LBG matrices due the utilization of synergistic interaction between two biopolymers and lower average size of this allowing a uniformity with the tablet hydration in dissolution media.
Export Options
About this article
Cite this article as:
Venkataraju P. M., Gowda V. D., Rajesh S. K and Shivakumar G. H., Xanthan and Locust Bean Gum (from Ceratonia siliqua) Matrix Tablets for Oral Controlled Delivery of Metoprolol Tartrate, Current Drug Therapy 2008; 3 (1) . https://dx.doi.org/10.2174/157488508783331216
DOI https://dx.doi.org/10.2174/157488508783331216 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Transmucosal Drug Delivery- An Overview
Drug Delivery Letters New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews subject Index To Volume 3
Current Drug Metabolism Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Anemia in Chronic Heart Failure - Clinical and Prognostic Significance
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Halogen Dance Reaction and its Application in Organic Synthesis
Current Organic Chemistry Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry